Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
1 hedge funds and large institutions have $75.4K invested in Terns Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 314 closing their positions.
100% less funds holding
Funds holding: 319 → 1 (-318)
100% less funds holding in top 10
Funds holding in top 10: 25 → 0 (-25)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $6.48B
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 314
142.57% less ownership
Funds ownership: 142.58% → 0% (-143%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$505M |
| 2 |
Morgan Stanley
New York
|
-$340M |
| 3 |
Avoro Capital Advisors
New York
|
-$300M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$230M |
| 5 |
Holocene Advisors
New York
|
-$217M |
TERN Hedge Fund Activity: Q2 2026 in Review
1 of the 8,377 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q2 2026, worth a combined $75.4K — down 100% from $6.56B a quarter earlier.
Sellers outnumbered buyers: 314 funds closed out of TERN and 0 opened new positions — a net loss of 314 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $505M sold.
- 1 institutional investor held Terns Pharmaceuticals (TERN) as of Q2 2026, down from 319 in Q1 2026.
- Funds reported $75.4K of Terns Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new Terns Pharmaceuticals positions in Q2 2026 and 314 closed out, a net change of -314 holders.
- The largest Terns Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $505M sold.
Based on aggregated 13F filings for Q2 2026.